| Description | KLH45 is an effective and selective inhibitor of Spastic Paraplegia-Related Triglyceride Hydrolase DDHD2(IC50 = 1.3 nM). |
| In vitro | In Neuro2A cells, KLH45 (25 nM) completely inhibits DDHD2 (>95%)[1]. In fatty acid-supplemented DDHD2-expressing cells, KLH45 (2 μM) increases LD formation and selectively blocks DDHD2 activity[2]. |
| In vivo | KLH45 (20 mg/kg) significantly elevates brain triglycerides in DDHD2−/− mice[1]. |
| Synonyms | KLH-45, KLH 45 |
| molecular weight | 458.48 |
| Molecular formula | C24H25F3N4O2 |
| CAS | 1632236-44-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 162.0 mg/mL (353.3 mM), Sonication is recommended. |
| References | 1. Jordon M Inloes, et al. The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14924-9. 2. Jordon M Inloes, et al. Functional Contribution of the Spastic Paraplegia-Related Triglyceride Hydrolase DDHD2 to the Formation and Content of Lipid Droplets. Biochemistry. 2018 Feb 6;57(5):827-838. |